Shingles

Individuals with a history of shingles was significantly and independently connected with a 20% higher risk of for subjective cognitive decline.

The findings indicate that zoster vaccine recombinant reduced dementia risk by 17% in an analysis of over 200,000 patients.

The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.

In a recent study, approximately 99% of children who received solid organ transplant and live vaccination against rubella had antibodies 1 to 3 months post-vaccination.

Moderna has advanced 6 programs into late-stage development, including for respiratory conditions, latent and other viruses, oncology, and rare diseases.

Vaccination is especially important for older adults with any chronic health conditions because vaccines can prevent serious illness and resulting complications down the road.

It is possible that the pandemic had a positive impact on influenza vaccination rates.

Staff members, especially immunizers, should look at every encounter as an opportunity to educate, support patients.

Due to the success of mRNA technology with COVID-19, there has been a significant increase in research looking into utilizing mRNA technology, and more specifically, how it can help to advance vaccine development.

Case studies highlight questions about shingles.

Letermovir is the only drug approved for prophylaxis of cytomegalovirus (CMV) infection for patients who are CMV-seropositive and have received an allogeneic HSCT.

IQVIA report states that appropriate reimbursement for all health care professionals who provide immunization services would encourage their ongoing provision of vaccines.

Across all vaccines for adults, regardless of income, location, or sex, most of the administration took place in a pharmacy, report shows.

Vaccination provides an opportunity to prevent and treat herpes simplex virus infection.

Herpes simplex virus type 2 is a common infection that is largely considered innocuous, but the study estimates that the economic burden may be substantial.

From newsworthy moments to groundbreaking research, these are the most popular articles in the zoster space, published on Pharmacy Times® during 2022.

Associated postherpetic neuralgia risk factors are history of diabetes mellitus, age, and immune-related disease.

Herpes zoster and postherpetic neuralgia can cause a significant health burden among adults 65 years of age and older.

An effective shingles vaccine has been available in China since 2020, but vaccine hesitancy persists in at-risk populations.

Novel mutations in the gene GTF3A impairs the innate immune response to herpes simplex virus 1.

Subgroup analyses suggest that a primary dose of the COVID-19 vaccine does not increase risk of herpes zoster infection, regardless of age, immunocompromised status, and type of vaccine administered.

Tetracyclines have been shown to offer some degree of immune protection resulting in mucosal healing, and in this study, they had one of the smaller associations with herpes zoster.

A session presenter at the ASCP 2022 Annual Meeting explained how the COVID-19 pandemic significantly magnified the importance of infection prevention and control practices in long-term care.

Herpes zoster can increase the risk of stroke, especially among patients under 40 years of age, for whom the vaccine is not typically recommended.

The objective of the trial was to compare letermovir with valganciclovir in preventing CMV disease in adults who received a kidney transplant and who are at high risk for CMV disease.